← Back to Search

CAR T-cell Therapy

BPX-601 for Prostate Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Bellicum Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through phase 1 completion, up to 5 years

Awards & highlights

Study Summary

This trial is testing a new cancer treatment where patients' T cells are modified to target and attack cancer cells with the protein marker PSCA.

Eligible Conditions

Metastatic Castration Resistant Prostate Cancer
Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through phase 1 completion, up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through phase 1 completion, up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and through phase 1 completion, up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose Limiting Toxicity

Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)

Therapeutic procedure

Secondary outcome measures

Antitumor activity of BPX-601

Pharmacodynamics (PD) of BPX-601

Trial Design

2Treatment groups

Experimental Treatment

Group I: Arm 2: Phase 2 Dose ExpansionExperimental Treatment2 Interventions

Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.

Group II: Arm 1: Phase 1 Dose EscalationExperimental Treatment2 Interventions

Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Rimiducid

Not yet FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bellicum PharmaceuticalsLead Sponsor

27 Previous Clinical Trials

1,201 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current vacancies for this clinical trial?

"Yes, this is an active study that was posted on November 1st, 2016 according to information available on clinicaltrials.gov."

Answered by AI

What is the current enrollment for this research project?

"Yes, the data on clinicaltrials.gov says that this study is presently recruiting patients. The study was initially posted on 11/1/2016 and was last edited on 8/10/2022. The study is recruiting for 151 patients across 13 sites."

Answered by AI

Is there any past research on BPX-601?

"As of right now, there are 16 clinical trials researching BPX-601 with 0 in Phase 3. Many of the studies for BPX-601 are running out of Nashville, Tennessee, but there are 94 locations running clinical trials for BPX-601."

Answered by AI

How many different medical clinics are running this trial today?

"There are 13 locations currently recruiting patients for this trial. Some of these include Roswell Park Cancer Institute in Buffalo, John Theurer Cancer Center, Hackensack University Medical Center in Hackensack, and University of Chicago Medicine in Chicago."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

2016. "Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02744287.